Bevacizumab and risk of intracranial hemorrhage in patients with brain metastases: a meta-analysis


Administration of bevacizumab to patients with brain metastases (BM) is controversial due to concerns about the increased risk of intracranial hemorrhage (ICH). This meta-analysis assessed whether the risk of ICH increases in BM patients receiving treatments that contain bevacizumab versus without. PubMed, Embase, Cochrane Library and annual meeting… (More)
DOI: 10.1007/s11060-017-2693-4


4 Figures and Tables

Slides referencing similar topics